HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Delayed percutaneous transluminal coronary angioplasty after acute myocardial infarction.

Abstract
The value of delayed percutaneous transluminal coronary angioplasty (> 12 h from admission or after thrombolytic therapy) following acute myocardial infarction is controversial. We compared the short- and long-term prognosis of 1940 consecutive patients after acute myocardial infarction, of whom 188 underwent delayed percutaneous transluminal coronary angioplasty. Delayed percutaneous transluminal coronary angioplasty was more frequently done in patients treated with thrombolysis (12%) than among patients excluded from thrombolytic therapy (8%; P=0.005). Patients in the delayed percutaneous transluminal coronary angioplasty group were younger, included more men and smokers and had less in-hospital complications in comparison to patients who did not undergo delayed percutaneous transluminal coronary angioplasty. The crude 30-day and 1-year mortality rates were 3 and 6% among patients who underwent percutaneous transluminal coronary angioplasty vs. 14 and 21% (P<0.01 for each) among those without percutaneous transluminal coronary angioplasty, respectively. After multivariate analysis adjusted for confounding factors, delayed percutaneous transluminal coronary angioplasty was associated with 65 (RR=0.35; 90% CI 0.14-0.88) and 50% (RR=0.50; 90% CI 0.27-0.92) mortality risk reduction after 30 days and 1 year, respectively. In conclusion, delayed percutaneous transluminal coronary angioplasty applied to selected post-myocardial infarction patients upon clinical indication is safe and beneficial for the treatment of acute myocardial infarction in the community.
AuthorsA Caspi, S Gottlieb, S Behar
JournalInternational journal of cardiology (Int J Cardiol) Vol. 63 Issue 3 Pg. 199-204 (Feb 28 1998) ISSN: 0167-5273 [Print] Netherlands
PMID9578344 (Publication Type: Journal Article)
Topics
  • Aged
  • Angioplasty, Balloon, Coronary
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardial Infarction (drug therapy, mortality, therapy)
  • Odds Ratio
  • Survival Rate
  • Thrombolytic Therapy
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: